|
|
|
LifeScienceHistory.com - Check us out on Instagram
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
DURECT Corporation
| | | Phone: | (408) 777-1417 | Fax: | (408) 777-3577 | Year Established: | 1998 | Employees: | 170 | Ticker: | DRRX | Exchange: | NASDAQ | Main Contact: | Michael Arenberg, Senior VP, Business Development | | Other Contacts: | Myriam Theeuwes, Senior VP, Clinical Development Jean I. Liu, VP, Finance Andrew R. Miksztal, Ph.D, VP, Pharmaceutical R&D Matthew J. Hogan, CFO Jian Li, VP, Finance and Corporate Controller Felix Theeuwes, D.Sc., Chairman & CSO James E. Brown, DMV, President & CEO
| | Company Description | DURECT is a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY(R), POSIDUR(TM), ELADUR(TM), and TRANSDUR(R)-Sufentanil. DURECT's proprietaryoral, transdermal and injectable depot delivery technologies may enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs | |
|
|
|
|
|